NINE Company Profile

The company announced operating shortfall of $-2.556 millions, in the Jan 31 2023 report

While the November to January 31 2023 reporting season continues, many corporations have declared the respective earnings. Among them, have been several constituents of the Major Pharmaceutical Preparations industry. And now, ANIX announced operating shortfall of $-2.556 millions, for the November to January 31 2023 period.

For the fiscal second quarter of 2022 company reached break-even of $0.00 per share compare to $-0.01 a year before and from $-0.01 per share from the prior reporting season.

Sales remained unaffected to $0.00 millions from $0.01 millions in the same reporting season a year before and sequentially from $0.00 millions.

Between many companies, the USAU disclosed also its third quarter of 2022 effort

After the leaders in the Metal Mining sector, some smaller companies are impending with the results. USAU mentioned it has announced operating shortfall of $-2.268151 millions, for the third quarter of 2022.

The company reported a sharp decline of -13.613 %, in Sales, all along the financial third quarter of 2022

Underlining the financial third quarter of 2022 net profit per share soared by 1266.67 % to $0.41 per share, despite Sales decrease of -13.613 % to $4.37 millions, year on year.

A minor Contraction in Sales at Pure Bioscience Inc during the financial interval closing Jan 31 2023

For the second quarter of 2022 Pure Bioscience Inc lost money of $-0.01 per share compare to $-0.01 a year prior and from $-0.01 per share from the preceding reporting season.

Sales contracted by -4.567 % to $0.40 millions from $0.42 millions in the comparable reporting season a year prior and sequentially Sales fell by -15.711 % from $0.47 millions.